Details

Autor(en) / Beteiligte

• Santini, Daniele
• Daniele, Santini
• Barni, Sandro
• Sandro, Barni
• Intagliata, Salvatore
• Salvatore, Intagliata
• Falcone, Alfredo
• Alfredo, Falcone
• Ferraù, Francesco
• Francesco, Ferraù
• Galetta, Domenico
• Domenico, Galetta
• Moscetti, Luca
• Luca, Moscetti
• La Verde, Nicla
• Nicla, La Verde
• Ibrahim, Toni
• Toni, Ibrahim
• Petrelli, Fausto
• Fausto, Petrelli
• Vasile, Enrico
• Enrico, Vasile
• Ginocchi, Laura
• Laura, Ginocchi
• Ottaviani, Davide
• Davide, Ottaviani
• Longo, Flavia
• Flavia, Longo
• Ortega, Cinzia
• Cinzia, Ortega
• Russo, Antonio
• Antonio, Russo
• Badalamenti, Giuseppe
• Giuseppe, Badalamenti
• Collovà, Elena
• Elena, Collovà
• Lanzetta, Gaetano
• Gaetano, Lanzetta
• Mansueto, Giovanni
• Giovanni, Mansueto
• Adamo, Vincenzo
• Vincenzo, Adamo
• De Marinis, Filippo
• Filippo, De Marinis
• Satolli, Maria Antonietta
• Cantile, Flavia
• Flavia, Cantile
• Mancuso, Andrea
• Andrea, Mancuso
• Tanca, Francesca Maria
• Addeo, Raffaele
• Raffaele, Addeo
• Russano, Marco
• Marco, Russano
• Sterpi, Michelle
• Sterpi, M
• Pantano, Francesco
• Francesco, Pantano
• Vincenzi, Bruno
• Bruno, Vincenzi
• Tonini, Giuseppe
• Giuseppe, Tonini

Titel

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Ist Teil von

• Scientific reports, 2015-12, Vol.5 (1), p.18670-18670, Article 18670

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.